# Adaptive Biotechnologies Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Adaptive Biotechnologies Corp).

## Overview

Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology. It develops clinical diagnostics and research tools that read T-cell and B-cell receptor signals from blood and tissue samples, then uses those data to support cancer monitoring, immune profiling, and drug discovery. The company’s commercial platform is anchored by clonoSEQ, an MRD test used in hematologic cancers, while its research and collaboration business includes Adaptive Immunosequencing and immune medicine programs. Adaptive also applies AI and machine learning to its immune receptor database to discover targets and characterize disease biology. The business sits at the intersection of diagnostics, research services, and therapeutic discovery, with revenue tied to clinical adoption, biopharma collaborations, and reimbursement coverage.

## Products & services

• clonoSEQ minimal residual disease (MRD) test
• MRD sample testing for biopharma and academic customers
• Adaptive Immunosequencing research services
• Immune Medicine collaboration and R&D support
• TCR/BCR sequencing, mapping, pairing and characterization
• TCR-antigen prediction and target discovery capabilities

- **Clinical diagnostics** (65%) — Commercial MRD testing and related clinical reporting for hematologic cancer monitoring, primarily through clonoSEQ.
- **Research services** (20%) — Sequencing and analysis services sold to biopharmaceutical companies and academic institutions for discovery and translational research.
- **Immune medicine collaborations** (15%) — Partner-funded R&D support, collaboration revenue, and milestone-linked programs such as the Genentech agreement.

- clonoSEQ minimal residual disease (MRD) test
- MRD sample testing for biopharma and academic customers
- Adaptive Immunosequencing research services
- Immune Medicine collaboration and R&D support
- TCR/BCR sequencing, mapping, pairing and characterization
- TCR-antigen prediction models and target discovery

## Customers

Adaptive sells to a mix of clinical, research, and biopharmaceutical customers. Its clinical customer base includes ordering physicians and the payors that reimburse clonoSEQ testing for patients with hematologic malignancies, so adoption depends on coverage, reimbursement, and clinical utility. On the research side, biopharmaceutical companies and academic institutions buy sequencing and analysis services to support drug discovery, biomarker work, and translational studies. The company also works with collaborators in immune medicine who fund platform access, sample testing, and R&D support to advance therapeutic programs. Customer demand is therefore driven by clinical adoption in MRD, the pace of biopharma R&D, and the success of partner programs.

- **Clinical MRD customers** (primary) — Physicians and health systems ordering clonoSEQ for disease monitoring in hematologic malignancies, with reimbursement and clinical utility driving use.
- **Biopharmaceutical customers** (primary) — Drug developers buying MRD sample testing, sequencing services, and platform access to support therapeutic development and biomarker discovery.
- **Academic and research institutions** (secondary) — Universities and research centers using Adaptive Immunosequencing and MRD services for translational research and investigator-led studies.
- **Immune medicine collaborators** (secondary) — Partners such as Genentech that fund R&D support and collaboration work to advance TCR-based and other immune medicine programs.

- Ordering physicians using clonoSEQ for MRD monitoring in blood cancers
- Commercial, government, and medical institution payors reimbursing clinical tests
- Biopharmaceutical companies buying sequencing and R&D support services
- Academic institutions using Adaptive Immunosequencing for research studies
- Therapeutic collaborators funding immune medicine platform access and milestones

## Geography

Adaptive is headquartered in Seattle, Washington and operates primarily as a U.S.-centric business. The company’s clinical revenue is tied to U.S. ordering physicians and U.S. payors, and management notes that clonoSEQ coverage has expanded to more than 300 million covered lives across Medicare, national private payors, and large regional plans. It also serves international laboratory sites through technology transfers, which adds some non-U.S. exposure but remains secondary to the domestic market. Because reimbursement, regulatory approval, and clinical adoption are central to the model, the U.S. market is the key geography for both revenue and operating strategy. The company’s research and collaboration work can also involve global biopharma partners, but the disclosed business remains concentrated in the United States.

- Headquartered in Seattle, Washington
- U.S. clinical market is the core revenue base for clonoSEQ
- Coverage expansion across Medicare and private payors supports U.S. adoption
- International technology transfer sites contribute a smaller portion of MRD activity
- Biopharma collaborations can be global, but revenue is still U.S.-weighted

## Strategy

Adaptive’s strategy is to expand clonoSEQ penetration in covered patient populations while broadening reimbursement and clinical adoption. At the same time, it is building a larger immune medicine platform by sequencing, mapping, and characterizing TCRs and BCRs at scale, then applying AI and machine learning to connect immune signatures with disease biology. The company is also trying to convert its data and technology base into multiple monetization paths, including research services, licensing, target discovery, and partner-funded R&D. Management emphasizes regulatory and reimbursement expertise as a competitive advantage because it lowers barriers to future clinical product development. The termination and wind-down of the Genentech agreement also make diversification and new partner programs important to replacing collaboration revenue over time.

- **Expand MRD clinical testing volume** (short-term) — Higher test volume improves operating leverage and strengthens the core clinical diagnostics franchise.
- **Build immune medicine discovery capabilities** (medium-term) — A larger data and analytics engine can create new research, licensing, and therapeutic opportunities beyond MRD.
- **Replace and diversify collaboration revenue** (medium-term) — Reducing dependence on any single partner program lowers revenue volatility after the Genentech wind-down.

- Increase clonoSEQ volume through deeper penetration of covered patients
- Expand reimbursement coverage and optimize payor access
- Use immune receptor sequencing data to build a larger discovery engine
- Apply AI and machine learning to TCR/BCR mapping and target discovery
- Grow research and collaboration revenue beyond a single partner program
- Leverage regulatory and reimbursement know-how to support new products

## Risks

Adaptive faces execution risk in a highly competitive and rapidly changing biotechnology market, where diagnostics, life sciences tools, and drug discovery companies all compete for the same customers and data. Its revenue depends heavily on clonoSEQ adoption, reimbursement coverage, and the timing of biopharma sample receipt and milestone recognition, which can create quarter-to-quarter volatility. The company also disclosed that the Genentech agreement has been terminated and is winding down, creating a material risk to Immune Medicine revenue and partner-related cash flows. Operationally, it relies on laboratory performance, data quality, intellectual property protection, and a limited number of suppliers for equipment and materials. More broadly, regulatory changes, reimbursement pressure, AI-related compliance issues, and slower-than-expected market acceptance could all reduce growth or delay profitability.

- **Genentech agreement termination and wind-down** [high] — Management disclosed that the agreement has been terminated and may materially affect business and financial condition because it had supported Immune Medicine revenue.
- **Reimbursement and coverage dependence** [high] — Clinical MRD adoption depends on payor coverage and reimbursement rates, which directly affect test volume and collectible revenue.
- **Competitive pressure in MRD and immune medicine** [medium] — The company competes with flow cytometry, ctDNA, and other emerging blood-based monitoring tools, which can limit market share and pricing power.
- **Supplier and laboratory operations risk** [medium] — The business depends on accurate lab execution and some single or limited suppliers for equipment and materials, creating operational fragility.
- **Regulatory and AI governance risk** [medium] — The company uses AI/ML and operates in a heavily regulated industry, so privacy, validation, and compliance failures could impair commercialization.

- Dependence on reimbursement and coverage decisions for clonoSEQ
- Revenue volatility from biopharma sample timing and milestone recognition
- Loss of Genentech collaboration revenue during wind-down
- Strong competition from flow cytometry, ctDNA, and other MRD methods
- Laboratory errors, assay defects, or supplier disruptions
- Regulatory and compliance risk in a heavily regulated diagnostics market
- AI and machine learning governance risk for data use and model outputs
- Intellectual property risk in a patent-intensive competitive field

## Accounting

Revenue recognition is a critical accounting area because Adaptive sells a mix of point-in-time clinical tests, over-time research services, upfront-funded collaborations, and milestone-based arrangements. For biopharma customers, the company records deferred revenue for upfront payments and recognizes revenue as sequencing results are delivered or services are performed, while some milestone revenue remains constrained until achievement becomes probable. Clinical MRD revenue also requires estimates of collectible amounts based on payor history, contracted reimbursement rates, and patient responsibility, which can materially affect reported revenue. The company notes that revenue can be recognized using a cumulative catch-up approach when sample estimates change or a project is cancelled, so revisions to expected volumes can shift revenue between periods. Investors should also watch goodwill, long-lived asset impairment, and the Purchase Agreement interest accretion, all of which rely on management estimates and can affect earnings and balance sheet values.

- **Revenue recognition across multiple contract types** — Can materially shift revenue between quarters and affect gross margin
- **Deferred revenue and cumulative catch-up adjustments** — Affects reported revenue timing and volatility
- **Collectability and reimbursement estimates** — Can change reported clinical revenue and receivables
- **Goodwill and long-lived asset impairment** — Potential non-cash charges to earnings
- **Purchase Agreement interest accretion** — Affects net loss and liability measurement

- Revenue recognition differs across clinical tests, research services, and collaborations
- Deferred revenue arises from non-refundable upfront payments by biopharma customers
- Clinical revenue depends on estimated reimbursement and collectability
- Milestone revenue is constrained until achievement becomes probable
- Cumulative catch-up adjustments can shift revenue when sample estimates change
- Goodwill and long-lived asset impairment require judgment and can affect earnings
- Imputing interest on the Purchase Agreement affects financing-related expense

---

*Last updated: 2026-08-11T04:46:19.479916+00:00*